The prevention and management of autosomal recessive conditions. Main example: alpha 1-antitrypsin deficiency

K H Gustavson1

  • 1Department of Clinical Genetics, University Hospital, Uppsala, Sweden.

Clinical Genetics
|November 1, 1989
PubMed

Insights

Newborn screening and genetic testing for treatable autosomal recessive disorders can improve health outcomes. Future approaches may include prenatal diagnosis and in-utero treatment for conditions like cystic fibrosis.

Area of Science:

  • Genetics
  • Public Health
  • Medical Screening

Background:

  • Autosomal recessive disorders are common in certain populations.
  • Early diagnosis and treatment are crucial for managing these conditions.
  • Advances in genetic testing are expanding screening possibilities.

Purpose of the Study:

  • To explore the benefits of newborn screening for treatable autosomal recessive disorders.
  • To discuss the potential of carrier screening and prenatal diagnosis for severe, non-treatable disorders.
  • To highlight future directions in fetal and newborn treatment.

Main Methods:

  • Review of current screening and diagnostic practices for genetic disorders.
  • Discussion of emerging technologies in genetic carrier testing and prenatal diagnosis.
  • Exploration of potential therapeutic interventions for affected fetuses and newborns.

Main Results:

  • Newborn screening is effective for treatable disorders like alpha-1-antitrypsin deficiency (alpha 1-AT).
  • Carrier testing for conditions such as cystic fibrosis is becoming increasingly available.
  • Prenatal diagnosis allows for informed reproductive choices.

Conclusions:

  • Population screening and early intervention significantly improve management of genetic disorders.
  • Genetic carrier screening and prenatal diagnosis offer valuable reproductive options.
  • Future research aims for in-utero treatment and correction of genetic disorders.

Related Concept Videos

Pedigree Analysis01:35

Pedigree Analysis

Overview
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...